Oral and late-breaking oral presentations will
highlight data from Phase 2 IGNAZ study in IgA nephropathy and
Phase 2 data in antibody-mediated rejection
SOUTH
SAN FRANCISCO, Calif., March 29,
2024 /PRNewswire/ -- Human Immunology Biosciences
(HI-Bio™), a clinical-stage biotechnology company developing
targeted therapies for patients with severe immune-mediated
diseases (IMDs), today announced that two abstracts have been
accepted for oral presentation at the 61st European Renal
Association (ERA) Congress, taking place May
23-26, 2024, in Stockholm
and in a virtual format. Presentations will include data from the
Phase 2 IGNAZ trial of felzartamab in patients with IgA nephropathy
(IgAN) and a late-breaking oral presentation of complete Phase 2
data from the investigator-sponsored study of felzartamab in
antibody-mediated rejection (AMR) in kidney transplant recipients.
The presentations reflect the first clinical data from felzartamab
in these indications, and the first clinical data from HI-Bio
development programs with felzartamab beyond primary membranous
nephropathy (PMN).
Oral Presentations
Abstract Title: Felzartamab (anti-CD38) in Patients
with IgA Nephropathy - Interim Results from the IGNAZ Study
Session Topic: Glomerular, tubulo-Interstitial diseases
& general nephrology
Subtopic: B4 - Prevention, Treatment and Clinical
Trials
Date and Time: May 24, 2024, 12:54 –
13:03 CEST (Moderated Orals 1.2, Room T5)
Presenter: Jürgen Floege, M.D., RWTH Aachen
University
Abstract Title: Randomized Phase 2 Trial of Felzartamab
in Humoral Transplant Rejection
Session Topic: Institutional
Subtopic: E3 - Treatment & Clinical Trials
Date and Time: May 25, 2024,
12:30 – 12:45 CEST (Late Breaking
Clinical Trials II, Victoria
Hall)
Presenter: Katharina A.
Mayer, M.D., Medical University of Vienna
For more information, please visit the 61st ERA Congress
website.
About Felzartamab
Felzartamab is an investigational
therapeutic human monoclonal antibody directed against CD38, a
protein expressed on mature plasma cells. Felzartamab has been
shown in clinical studies to selectively deplete CD38+ plasma
cells, which may allow applications that ultimately improve
clinical outcomes in a broad range of diseases driven by pathogenic
antibodies.
HI-Bio is focused on developing felzartamab in a number of
immune-mediated diseases, including antibody-mediated rejection
(AMR), IgA nephropathy (IgAN), lupus nephritis (LN) and primary
membranous nephropathy (PMN). Felzartamab has received Breakthrough
Therapy designation and Orphan Drug Designation from the FDA for
development in the treatment of PMN, and Orphan Drug Designation in
the treatment of AMR in kidney transplant recipients.
HI-Bio in-licensed felzartamab from MorphoSys in 2022 and holds
exclusive worldwide rights for felzartamab with the exception of
Greater China.
Felzartamab is an investigational therapeutic candidate that has
not yet been approved by any regulatory authority.
About HI-Bio
Human Immunology Biosciences, Inc.
(HI-Bio™) is a clinical-stage biotechnology company focused on
discovering and developing precision medicines for people suffering
from immune-mediated diseases (IMDs). HI-Bio is
leading clinical immunology into its next chapter by targeting
cellular drivers of disease. To learn more about HI-Bio, visit us
at www.hibio.com or follow us on LinkedIn
and X.
Contact
Morgan Warners
FGS Global
morgan.warners@fgsglobal.com
|
Caroline Fry
FGS Global
caroline.fry@fgsglobal.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hi-bio-to-present-at-the-61st-european-renal-association-era-congress-302103190.html
SOURCE HI-Bio